7th May 2026 10:00
Novacyt S.A.
("Novacyt" or the "Company")
Directorate Change
Paris, France and Manchester, UK - 7 May 2026 - Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces that Dr Joanne Mason is stepping down as Chief Scientific Officer and a member of the Board of Novacyt, with immediate effect, to enable her to pursue other business opportunities.
Lyn Rees, Chief Executive Officer of Novacyt, commented: "Throughout Jo's six-year tenure, she has been instrumental in shaping our scientific direction and strengthening the foundations of our research and development work. Her leadership and expertise have made a meaningful impact, and we are grateful for the dedication she has shown to the organisation. We thank Jo for her contribution to the business and wish her every success in the future."
Contacts
Novacyt SA | https://novacyt.com/investors | |||
Lyn Rees, Chief Executive Officer | Via Walbrook PR | |||
Steve Gibson, Chief Financial Officer
| ||||
SP Angel Corporate Finance LLP (Nominated Adviser and Broker) | +44 (0)20 3470 0470 | |||
Matthew Johnson / Charlie Bouverat (Corporate Finance) Vadim Alexandre / Rob Rees (Corporate Broking) | ||||
Singer Capital Markets (Joint Broker) | +44 (0) 20 7496 3000 | |||
Phil Davies / James Fischer / Samed Ethemi | ||||
Allegra Finance (French Listing Sponsor) Rémi Durgetto / Yannick Petit | +33 (1) 42 22 10 10 [email protected] / [email protected] | |||
Walbrook PR (Financial PR & IR) Paul McManus / Lianne Applegarth Alice Woodings | +44 (0)20 7933 8780 or [email protected] +44 (0)7980 541 893 / +44 (0)7584 391 303 +44 (0)7407 804 654 | |||
About Novacyt Group (www.novacyt.com)
Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental.
The Company is divided into three business segments:
Clinical | Broad portfolio of human clinical in vitro diagnostic products, workflows and services focused on three therapeutic areas: · Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy tests · Precision Medicine: DPYD genotyping assay · Infectious Diseases: Winterplex, multiplex winter respiratory PCR panel
|
Instrumentation | Portfolio of next generation size selection DNA sample preparation platforms and rapid PCR machines, including: · Ranger® Technology: automated DNA sample preparation and target enrichment technology · genesig q16 and q32 real-time quantitative PCR (qPCR) instruments
|
Research Use Only | Range of services for the life sciences industry: · Design, manufacture, and supply of high-performance qPCR assays and workflows for use in human health, agriculture, veterinary and environmental, to support global health organisations and the research industry · Pharmaceutical research services: whole genome sequencing (WGS) / whole exome sequencing (WES) |
Novacyt is headquartered in Le Vésinet in France with offices in the UK (Manchester), Singapore, the US and Canada and has a commercial presence in over 65 countries, including Australia, following the recent acquisition of Southern Cross Diagnostics in March 2026, which has opened new distribution channels to the life sciences and diagnostics industries in the territory and the wider Asia-Pacific region. The Company is listed on the London Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext Growth ("ALNOV").
For more information, please refer to the website: www.novacyt.com
Related Shares:
Novacyt